Axsome Therapeutics, Inc. (NASDAQ:AXSM) is Alethea Capital Management LLC's Largest Position

Alethea Capital Management LLC trimmed its stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 0.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 734,317 shares of the company's stock after selling 4,186 shares during the period. Axsome Therapeutics comprises approximately 53.2% of Alethea Capital Management LLC's investment portfolio, making the stock its biggest position. Alethea Capital Management LLC owned approximately 1.52% of Axsome Therapeutics worth $62,131,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Assetmark Inc. acquired a new position in Axsome Therapeutics in the fourth quarter valued at $52,000. R Squared Ltd bought a new stake in shares of Axsome Therapeutics during the 4th quarter valued at about $64,000. Aquatic Capital Management LLC acquired a new stake in Axsome Therapeutics during the fourth quarter worth approximately $76,000. KBC Group NV grew its stake in Axsome Therapeutics by 40.5% during the fourth quarter. KBC Group NV now owns 1,336 shares of the company's stock worth $113,000 after purchasing an additional 385 shares during the period. Finally, Xponance Inc. lifted its stake in Axsome Therapeutics by 11.6% in the fourth quarter. Xponance Inc. now owns 2,659 shares of the company's stock valued at $225,000 after buying an additional 277 shares during the period. 81.49% of the stock is owned by institutional investors.

Axsome Therapeutics Stock Down 3.7 %

Shares of AXSM traded down $4.33 during midday trading on Tuesday, reaching $112.16. 716,105 shares of the stock were exchanged, compared to its average volume of 685,724. The company has a market capitalization of $5.52 billion, a P/E ratio of -18.72 and a beta of 0.46. The company has a current ratio of 2.11, a quick ratio of 2.04 and a debt-to-equity ratio of 3.22. Axsome Therapeutics, Inc. has a 52 week low of $64.11 and a 52 week high of $139.13. The company's 50 day moving average is $113.35 and its two-hundred day moving average is $104.18.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last issued its quarterly earnings data on Tuesday, February 18th. The company reported ($0.96) earnings per share for the quarter, topping analysts' consensus estimates of ($0.97) by $0.01. Axsome Therapeutics had a negative return on equity of 223.51% and a negative net margin of 74.47%. The firm had revenue of $118.77 million during the quarter, compared to analysts' expectations of $117.83 million. On average, sell-side analysts anticipate that Axsome Therapeutics, Inc. will post -2.79 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on AXSM shares. William Blair reiterated an "outperform" rating on shares of Axsome Therapeutics in a report on Tuesday, February 18th. Mizuho upped their price target on Axsome Therapeutics from $212.00 to $216.00 and gave the stock an "outperform" rating in a research note on Thursday, March 27th. Cantor Fitzgerald reissued an "overweight" rating and issued a $153.00 price objective on shares of Axsome Therapeutics in a research note on Wednesday, February 19th. Royal Bank of Canada upped their target price on Axsome Therapeutics from $190.00 to $193.00 and gave the stock an "outperform" rating in a research report on Tuesday, April 29th. Finally, Robert W. Baird boosted their price target on shares of Axsome Therapeutics from $160.00 to $162.00 and gave the company an "outperform" rating in a research note on Tuesday. One investment analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $170.33.

Insider Buying and Selling at Axsome Therapeutics

In related news, CFO Nick Pizzie sold 3,000 shares of the business's stock in a transaction on Friday, February 14th. The shares were sold at an average price of $131.07, for a total transaction of $393,210.00. Following the completion of the transaction, the chief financial officer now directly owns 42,187 shares in the company, valued at $5,529,450.09. The trade was a 6.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 22.40% of the company's stock.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.